Exhibit 10.2
REVOLUTION MEDICINES, INC.
EMPLOYMENT AGREEMENT
This Employment Agreement (the “Agreement”), entered into effective as of August 1, 2024 (the “Effective Date”), is between Revolution Medicines, Inc., a Delaware corporation (the “Company”) and Jack Anders (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain Employment Agreement between Executive and the Company dated as of April 29, 2022 (the “Prior Agreement”).
WHEREAS, the Company desires to assure itself of the continued services of Executive by engaging Executive to perform services as an employee of the Company under the terms hereof;
WHEREAS, Executive desires to provide continued services to the Company on the terms herein provided; and
WHEREAS, the Parties desire to execute this Agreement to supersede the Prior Agreement in its entirety and reflect certain changes to Executive’s employment with the Company effective as of the Effective Date.
NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, including the respective covenants and agreements set forth below, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:
1
Exhibit 10.2
2
Exhibit 10.2
3
Exhibit 10.2
4
Exhibit 10.2
5
Exhibit 10.2
6
Exhibit 10.2
Notwithstanding the foregoing definition or any other provision of this Agreement, the term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company. Further notwithstanding the foregoing, if a Change in Control constitutes a payment event hereunder that provides for the deferral of compensation that is subject to Section 409A, to the extent required to avoid the imposition of additional taxes under Section 409A, the transaction or event described in subsection (i), (ii), (iii) or (v) of this Section 6(g) with respect to such payment shall only constitute a Change in Control for purposes of payment timing if such transaction also constitutes a “change in control event,” as defined in Treasury Regulation Section 1.409A-3(i)(5).
7
Exhibit 10.2
8
Exhibit 10.2
9
Exhibit 10.2
10
Exhibit 10.2
11
Exhibit 10.2
12
Exhibit 10.2
[Signature Page Follows]
13
The Parties have executed this Agreement as of the date first set forth above.
REVOLUTION MEDICINES, INC.
By: /s/ Mark Goldsmith
Name: Mark Goldsmith
Title: Chief Executive Officer
EXECUTIVE
By: /s/ Jack Anders
Name: Jack Anders
Exhibit 10.2
Exhibit A
RELEASE OF CLAIMS
This Release of Claims (“Release”) is entered into as of _________________, 20__, between [__________] (“Executive”) and Revolution Medicines, Inc., a Delaware corporation (the “Company” and, together with Executive, the “Parties”), effective eight days after Executive’s signature hereto (the “Effective Date”), unless Executive revokes Executive’s acceptance of this Release as provided in Paragraph 1(c), below.
Exhibit 10.2
Exhibit 10.2
“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.”
BEING AWARE OF SAID CODE SECTION, EXECUTIVE HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.
Exhibit 10.2
Exhibit 10.2
IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed the foregoing on the dates shown below.
EXECUTIVE REVOLUTION MEDICINES, INC.
__________________________ __________________________
By:
Title:
Date: ______________________ Date: _____________________